Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel 120 mg as primary medical treatment in acromegalic patients with macroadenoma
2007-000155-34Phase 3Completed
- Sponsor
- Ipsen
- Start
- Feb 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanreotide in acromegaly, sponsored by Ipsen. Primary endpoint: Significant reduction in tumor volume at Week 48. Started Feb 2008; status: completed.
02
Drugs
lanreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2007-000155-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000155-34.